AstraZeneca's License Of Ionis NASH Candidate Illustrates Still Hot Competition

Along with last week's acquisition of three NASH candidates from Lilly by Terns, NASH remains a heavily crowded R&D space as the European Association for the Study of the Liver annual meeting approaches.

Businessman touched r and d sign. R d icon network business concept word cloud background tag. R&D: Research and development word lettering typography design illustration with line icons and ornaments

Heading into the International Liver Congress, deal-making began to heat up again in the frenzied non-alcoholic steatohepatitis space, as AstraZeneca PLC in-licensed a candidate from Ionis Pharmaceuticals Inc. on April 9 under the two companies' R&D collaboration. A few days prior, Eli Lilly & Co. out-licensed its three NASH candidates to Terns Pharmaceuticals Inc., a start-up Lilly's Asian venture arm funded just a year earlier.

AstraZeneca's pick up of IONIS-AZ6-2.5-L RX, to be known going forward as AZD2693, makes it the 11th big or specialty...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category